Corporate R&D StrategyNVIDIA's BioNeMo Becomes Pharma's AI Backbone as Novo Nordisk Offloads Parkinson's Risk to AI PartnerSalvado•Jun 27, 2026
Healthcare & BiotechNovo Nordisk Exits Internal Parkinson's Unit, Licenses Program to AI Partner Cellular IntelligenceSalvado•Jun 25, 2026
Corporate StrategyNovo Nordisk Exits Cell Therapy, Hands Parkinson's Assets to AI Startup as Pharma Rewires R&DSalvado•Jun 19, 2026
Pharmaceutical StrategyNovo Nordisk Licenses Parkinson's Cell Therapy to AI Partner, Shutters Internal UnitSalvado•Jun 5, 2026
Pharma StrategyNovo Nordisk's 24.9% Rally Validates AI Licensing Over Internal Cell TherapySalvado•May 31, 2026
Corporate StrategyNovo Nordisk Closes Internal Cell Therapy Unit, Licenses Program to AI-Native Cellular IntelligenceSalvado•May 21, 2026
Corporate Strategy & Business TransformationNovo Nordisk's 25% Stock Surge Validates Pharma's Pivot to AI Platform OutsourcingSalvado•May 18, 2026
